PDF, 19 pages:
http://stocknessmonster.com/news-item?S=EPT&E=ASX&N=208441
"Phase I/IIa clinical trial successfully completed at Royal Adelaide Hospital in March 2002.
Phase IIb “sunburn” trial will finish mid September 2003 with preliminary results due early November.
The company fully expects results will show that
sunburn damage is markedly reduced following Melanotan treatment.
Sustained release formulation developed in collaboration with SRI (Alabama, USA). This (new) formulation in the form of a small implant is designed to be placed under the skin.
Phase I/II (human) clinical trials will begin at Q-Pharm, Brisbane in November.
Collaborative agreement with CollaGenex and Thomas Sköld to develop a
topical formulation using Restoraderm™ technology".
- Forums
- ASX - By Stock
- CUV
- company presentation
company presentation
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.36 |
Change
0.180(1.27%) |
Mkt cap ! $719.8M |
Open | High | Low | Value | Volume |
$14.08 | $14.60 | $14.03 | $1.210M | 84.62K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $14.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.36 | 3 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 14.350 |
1 | 302 | 14.320 |
1 | 302 | 14.290 |
1 | 209 | 14.270 |
1 | 302 | 14.260 |
Price($) | Vol. | No. |
---|---|---|
14.360 | 3 | 1 |
14.380 | 417 | 1 |
14.400 | 2000 | 1 |
14.460 | 2392 | 2 |
14.480 | 302 | 1 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
$14.37 |
  |
Change
0.180 ( 1.60 %) |
|||
Open | High | Low | Volume | ||
$14.45 | $14.49 | $14.05 | 9640 | ||
Last updated 15.59pm 28/03/2024 ? |
Featured News
CUV (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online